Skip to main content
NCBI home page
Protein Science : A Publication of the Protein Society logoLink to Protein Science : A Publication of the Protein Society
. 1999 Jan;8(1):91–95. doi: 10.1110/ps.8.1.91

The crystal structure of alpha-thrombin-hirunorm IV complex reveals a novel specificity site recognition mode.

A Lombardi 1, G De Simone 1, F Nastri 1, S Galdiero 1, R Della Morte 1, N Staiano 1, C Pedone 1, M Bolognesi 1, V Pavone 1
PMCID: PMC2144104  PMID: 10210187

Abstract

The X-ray crystal structure of the human alpha-thrombin-hirunorm IV complex has been determined at 2.5 A resolution, and refined to an R-factor of 0.173. The structure reveals an inhibitor binding mode distinctive of a true hirudin mimetic, which justifies the high inhibitory potency and the selectivity of hirunorm IV. This novel inhibitor, composed of 26 amino acids, interacts through the N-terminal end with the alpha-thrombin active site in a nonsubstrate mode, and binds specifically to the fibrinogen recognition exosite through the C-terminal end. The backbone of the N-terminal tripeptide Chg1"-Arg2"-2Na13" (Chg, cyclohexyl-glycine; 2Na1, beta-(2-naphthyl)-alanine) forms a parallel beta-strand to the thrombin main-chain segment Ser214-Gly216. The Chg1" side chain occupies the S2 site, Arg2" penetrates into the S1 specificity site, while the 2Na13" side chain occupies the aryl binding site. The Arg2" side chain enters the S1 specificity pocket from a position quite apart from the canonical P1 site. This notwithstanding, the Arg2" side chain establishes the typical ion pair with the carboxylate group of Asp189.

Full Text

The Full Text of this article is available as a PDF (738.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abola E. E., Sussman J. L., Prilusky J., Manning N. O. Protein Data Bank archives of three-dimensional macromolecular structures. Methods Enzymol. 1997;277:556–571. doi: 10.1016/s0076-6879(97)77031-9. [DOI] [PubMed] [Google Scholar]
  2. Ascenzi P., Amiconi G., Bode W., Bolognesi M., Coletta M., Menegatti E. Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects. Mol Aspects Med. 1995;16(3):215–313. doi: 10.1016/0098-2997(95)00002-x. [DOI] [PubMed] [Google Scholar]
  3. Bode W., Mayr I., Baumann U., Huber R., Stone S. R., Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989 Nov;8(11):3467–3475. doi: 10.1002/j.1460-2075.1989.tb08511.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bode W., Turk D., Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1992 Apr;1(4):426–471. doi: 10.1002/pro.5560010402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brandstetter H., Turk D., Hoeffken H. W., Grosse D., Stürzebecher J., Martin P. D., Edwards B. F., Bode W. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. J Mol Biol. 1992 Aug 20;226(4):1085–1099. doi: 10.1016/0022-2836(92)91054-s. [DOI] [PubMed] [Google Scholar]
  6. De Simone G., Lombardi A., Galdiero S., Nastri F., Della Morte R., Staiano N., Pedone C., Bolognesi M., Pavone V. Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex. Protein Sci. 1998 Feb;7(2):243–253. doi: 10.1002/pro.5560070203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Di Cera E., Dang Q. D., Ayala Y. M. Molecular mechanisms of thrombin function. Cell Mol Life Sci. 1997 Sep;53(9):701–730. doi: 10.1007/s000180050091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fenton J. W., 2nd, Bing D. H. Thrombin active-site regions. Semin Thromb Hemost. 1986 Jul;12(3):200–208. doi: 10.1055/s-2007-1003551. [DOI] [PubMed] [Google Scholar]
  9. Fenton J. W., 2nd Thrombin specificity. Ann N Y Acad Sci. 1981;370:468–495. doi: 10.1111/j.1749-6632.1981.tb29757.x. [DOI] [PubMed] [Google Scholar]
  10. Féthière J., Tsuda Y., Coulombe R., Konishi Y., Cygler M. Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human alpha-thrombin. Protein Sci. 1996 Jun;5(6):1174–1183. doi: 10.1002/pro.5560050620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Grütter M. G., Priestle J. P., Rahuel J., Grossenbacher H., Bode W., Hofsteenge J., Stone S. R. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J. 1990 Aug;9(8):2361–2365. doi: 10.1002/j.1460-2075.1990.tb07410.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jones T. A., Zou J. Y., Cowan S. W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A. 1991 Mar 1;47(Pt 2):110–119. doi: 10.1107/s0108767390010224. [DOI] [PubMed] [Google Scholar]
  13. Lombardi A., Nastri F., Della Morte R., Rossi A., De Rosa A., Staiano N., Pedone C., Pavone V. Rational design of true hirudin mimetics: synthesis and characterization of multisite-directed alpha-thrombin inhibitors. J Med Chem. 1996 May 10;39(10):2008–2017. doi: 10.1021/jm950898g. [DOI] [PubMed] [Google Scholar]
  14. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res. 1994 Apr 1;74(1):1–23. doi: 10.1016/0049-3848(94)90032-9. [DOI] [PubMed] [Google Scholar]
  15. Pavone V., De Simone G., Nastri F., Galdiero S., Staiano N., Lombardi A., Pedone C. Multiple binding mode of reversible synthetic thrombin inhibitors. A comparative structural analysis. Biol Chem. 1998 Aug-Sep;379(8-9):987–1006. [PubMed] [Google Scholar]
  16. Rydel T. J., Ravichandran K. G., Tulinsky A., Bode W., Huber R., Roitsch C., Fenton J. W., 2nd The structure of a complex of recombinant hirudin and human alpha-thrombin. Science. 1990 Jul 20;249(4966):277–280. doi: 10.1126/science.2374926. [DOI] [PubMed] [Google Scholar]
  17. Rydel T. J., Tulinsky A., Bode W., Huber R. Refined structure of the hirudin-thrombin complex. J Mol Biol. 1991 Sep 20;221(2):583–601. doi: 10.1016/0022-2836(91)80074-5. [DOI] [PubMed] [Google Scholar]
  18. Schechter I., Berger A. On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun. 1967 Apr 20;27(2):157–162. doi: 10.1016/s0006-291x(67)80055-x. [DOI] [PubMed] [Google Scholar]
  19. Skrzypczak-Jankun E., Carperos V. E., Ravichandran K. G., Tulinsky A., Westbrook M., Maraganore J. M. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J Mol Biol. 1991 Oct 20;221(4):1379–1393. [PubMed] [Google Scholar]
  20. Steiner V., Knecht R., Börnsen K. O., Gassmann E., Stone S. R., Raschdorf F., Schlaeppi J. M., Maschler R. Primary structure and function of novel O-glycosylated hirudins from the leech Hirudinaria manillensis. Biochemistry. 1992 Mar 3;31(8):2294–2298. doi: 10.1021/bi00123a012. [DOI] [PubMed] [Google Scholar]
  21. Strube K. H., Kröger B., Bialojan S., Otte M., Dodt J. Isolation, sequence analysis, and cloning of haemadin. An anticoagulant peptide from the Indian leech. J Biol Chem. 1993 Apr 25;268(12):8590–8595. [PubMed] [Google Scholar]
  22. Stubbs M. T., Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res. 1993 Jan 1;69(1):1–58. doi: 10.1016/0049-3848(93)90002-6. [DOI] [PubMed] [Google Scholar]
  23. Tabernero L., Chang C. Y., Ohringer S. L., Lau W. F., Iwanowicz E. J., Han W. C., Wang T. C., Seiler S. M., Roberts D. G., Sack J. S. Structure of a retro-binding peptide inhibitor complexed with human alpha-thrombin. J Mol Biol. 1995 Feb 10;246(1):14–20. doi: 10.1006/jmbi.1994.0060. [DOI] [PubMed] [Google Scholar]
  24. Tapparelli C., Metternich R., Ehrhardt C., Cook N. S. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol Sci. 1993 Oct;14(10):366–376. doi: 10.1016/0165-6147(93)90095-2. [DOI] [PubMed] [Google Scholar]
  25. Vitali J., Martin P. D., Malkowski M. G., Robertson W. D., Lazar J. B., Winant R. C., Johnson P. H., Edwards B. F. The structure of a complex of bovine alpha-thrombin and recombinant hirudin at 2.8-A resolution. J Biol Chem. 1992 Sep 5;267(25):17670–17678. [PubMed] [Google Scholar]
  26. van de Locht A., Stubbs M. T., Bode W., Friedrich T., Bollschweiler C., Höffken W., Huber R. The ornithodorin-thrombin crystal structure, a key to the TAP enigma? EMBO J. 1996 Nov 15;15(22):6011–6017. [PMC free article] [PubMed] [Google Scholar]

Articles from Protein Science : A Publication of the Protein Society are provided here courtesy of The Protein Society

RESOURCES